Citicoline 1g 6 Months: Ischemic Stroke Cognition +28%, Motor Recovery +35% RCT
Citicoline (CDP-choline) 1g/day for 6 months improved cognitive function (MMSE) by 28%, motor recovery (NIHSS) by 35%, daily living independence (Barthel index) by 32%, depression (BDI) by 28%, and quality of life (SF-36) by 35% in 380 ischemic stroke patients, per a 2026 Stroke (AHA) RCT. Recovery matrix validation for the era of 110,000+ annual stroke cases in Korea, with 60%+ experiencing cognitive and motor sequelae.
The study followed acute ischemic stroke patients (within 14 days of onset) over 6 months in a randomized double-blind design. Citicoline 1,000mg/day (oral) + standard rehab vs placebo + standard rehab. Results: MMSE +28% (24 → 26.5), NIHSS -35% (8 → 5.2), Barthel +32% (55 → 73), BDI -28% (18 → 13), SF-36 +35%, MRI gray matter volume +12%, BDNF +25%. Side effects: minimal.
Citicoline — Core Molecule for Phosphatidylcholine Synthesis
What it is:
- CDP-choline (cytidine diphosphate choline) = citicoline
- Direct precursor for phosphatidylcholine (PC) synthesis
- Core phospholipid (50%+) of neuronal membranes
- 1980s standard stroke treatment in Japan and Europe (Somazina, Ceraxon)
Mechanisms:
- Provides neuronal membrane PC + choline + cytidine
- Acetylcholine synthesis ↑ → cognitive function recovery
- BDNF, NGF, VEGF neurotrophic factor elevation
- Glutamate excitotoxicity block → neuroprotection
- Cerebral microcirculation +25% (vasodilation)
Ischemic Stroke — Korea 110,000+ Annually
Korean statistics:
- 110,000+ annual cases, 4th leading cause of death
- 80% in 60+, 60%+ have sequelae (motor, cognitive, language)
- Golden time 3-4.5 hours (tPA thrombolysis)
- Citicoline matrix is core during 6+ month recovery phase
Recovery stages:
- Acute (1-14 days): tPA, thrombectomy + neuroprotection
- Subacute (2-4 weeks): Rehab start + citicoline initiation
- Chronic recovery (1-6 months): Rehab + matrix accumulation
- 6+ months evaluation (BDNF, neuroplasticity core)
1g/day — 6-Month Cumulative Critical Dose
Dose matrix:
- 250-500mg: General cognitive support (prevention, aging)
- 1,000mg/day: Stroke recovery matrix (current RCT)
- 2,000mg/day: Acute neuroprotection (IV available)
- 6+ months cumulative evaluation
Korean market:
- Pharmaceutical (Somazina, Corin): physician prescription, insurance
- OTC/supplement: 30,000-80,000 KRW per 30 days
- Standardized extracts (CDP-choline 90%+) preferred
Matrix — DHA, B12, Lion’s Mane Synergy
Stroke recovery matrix:
- Citicoline 1g/day (PC synthesis, acetylcholine)
- DHA 500mg/day (photoreceptor, brain membrane)
- Vitamin B12 1,000μg/day (homocysteine ↓)
- Lion’s mane 500mg/day (NGF, neuroplasticity)
- Standard rehabilitation (essential)
Cautions
Drug interactions:
- Anticoagulants and thrombolytics: physician evaluation (bleeding risk)
- SSRI antidepressants: physician evaluation
- Insufficient pregnancy/lactation data
- Take with meals (gastric protection)
Side effects:
- GI discomfort under 5%
- Headache 3%
- Allergic reactions rare
- 6+ months cumulative evaluation, with physician collaboration
Post-Stroke Cognitive Decline — Bidirectional Risk
Cascade:
- Stroke → gray matter damage → cognitive decline
- Cognitive decline → reduced rehab motivation → reduced motor recovery
- Reduced motor activity → reduced social activity → depression ↑
- Depression ↑ → additional cognitive decline → dementia risk +200%
Citicoline blocks:
- Neuroplasticity +25% → gray matter recovery
- Cognitive + motor simultaneous recovery → bidirectional effect
- Depression -28% → rehab motivation ↑
- 6+ months cumulative → reduced chronic cognitive sequelae
Global Stroke Recovery Market
Japan: Novartis Somazina pharmaceutical market 500 billion KRW+ Europe: Ferrer Ceraxon standard US: NIH 60+ stroke RCTs cumulative Korea: Post-2025 medical collaboration + supplement market growth
Spring 2026, citicoline 1g/day for 6 months validating ischemic stroke cognition +28%, motor recovery +35%, depression -28% marks not just supplements but a new standard for neuroplasticity recovery matrix. With DHA, B12, lion’s mane matrix, accompanied by standard rehabilitation.